In the shadow of Vertex, small cystic fibrosis-focused biotechs thrive

The undisputed leader in the field of drugs to treat cystic fibrosis is Boston’s Vertex Pharmaceuticals, but that company’s success is spurring some smaller, recently-public biotechs to focus on drugs to treat the inherited, fatal disease. Corbus Pharmaceuticals (Nasdaq: CRBP) in Norwood, which just started trading on the Nasdaq exchange in April, has attracted attention for its potential drug, Resunab, which is about to begin mid-stage trials to treat inflammation associated with CF. But in…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news